GATA
Etude de la combinaison de l'Atezolizumab avec le Venetoclax et l'Obinutuzumab dans les lymphomes B en rechute ou réfractaire (phase Ib-II) rechute ou réfractaire (phase Ib-II)Plaquette
| Poster GATA | ASCO 2021 |
|---|---|
| Charles Herbaux | Atezolizumab + Obniutuzumab + Venetoclax in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma in (R/R INHL): primary analysis of a Phase 2 trial from LYSA
|
| Communication orale GATA | EHA 2021 |
|---|---|
| Charles Herbaux | Atezolizumab + Obniutuzumab + Venetoclax in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma in (R/R INHL): primary analysis of a Phase 2 trial from LYSA
|
| Poster GATA | EHA 2021 |
|---|---|
| Yassine Al Tabaa | Prospective Evaluation of Lymphoma response to immunomodulatory therapy criteria (lyric) in GATA trial from the LYSA Group
|
| Posters GATA | ICMLugano 2021 |
|---|---|
| Charles Herbaux | Atezolizumab + Obinutuzumab + Venetoclax in patients with relapsed or refractory Marginal Zone Lymphoma: primary analysis of a phase 2 trial from LYSA
|
| Guillaume Cartron | Atezolizumab + Obinutuzumab + Venetoclax in patients with relapsed or refractory Follicular Lymphoma: primary analysis of a phase 2 trial from LYSA
|
| Yassine Al Tabaa | Prospective evaluation of lymphoma response to immunomodulatory therapy criteria (lyric) in GATA trial from the LYSA group
|
| Abstract book GATA | ICMLugano 2021 |
|---|---|
| Camille Laurent | A widespread T-cell exhaustion pattern is frequent in the tumor microenvironment of relapsed/refractory B-cell Lymphoma patients and could be circumvented by PDL1 blockade
|
| Poster GATA | ASCO 2020 |
|---|---|
| Charles Herbaux | Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA
|
| Communication orale GATA | EHA 2020 |
|---|---|
| Charles Herbaux | Efficacy and Safety of Atezolizumab + Obinutuzumab + Venetoclax in patients with relapsed or refractory Diffuse Large B-Cell Lymphomas: Primary analysis of a Phase 2 trial from LYSA
|
